Texcity Biosciences Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 17-12-2024
- Paid Up Capital ₹ 5.00 M
as on 17-12-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.33 Cr
as on 17-12-2024
- Revenue -16.91%
(FY 2022)
- Profit -21.54%
(FY 2022)
- Ebitda 1421.23%
(FY 2022)
- Net Worth 1.00%
(FY 2022)
- Total Assets -6.15%
(FY 2022)
About Texcity Biosciences
The Corporate was formerly known as Texcity Hybrid Seeds Coimbatore Private Limited. The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.33 Cr.
Subbia Pandithan, Subbaiaya Krishnamoorthy, and Coimbatore Rajendran serve as directors at the Company.
- CIN/LLPIN
U01122TZ2011PTC017486
- Company No.
017486
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Texcity Biosciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Coimbatore Rajendran  | Managing Director | 12-Oct-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subbia Pandithan | Director | 25-Jun-2013 | Current |
| Subbaiaya Krishnamoorthy | Director | 03-Dec-2012 | Current |
Financial Performance of Texcity Biosciences.
Texcity Biosciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 16.91% decrease. The company also saw a substantial fall in profitability, with a 21.54% decrease in profit. The company's net worth moved up by a moderate rise of 1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Texcity Biosciences?
In 2022, Texcity Biosciences had a public holding of 64.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 29 Apr 2020 | ₹0.25 M | Open |
Indian Bank Creation Date: 17 Feb 2017 | ₹4.50 M | Open |
Indian Bank Creation Date: 31 Mar 2015 | ₹8.50 M | Open |
How Many Employees Work at Texcity Biosciences?
Unlock and access historical data on people associated with Texcity Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Texcity Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Texcity Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
